From the beginning, the approval of its Aduhelm (aducanumab) treatment was met with controversy – over the interactions with the FDA, and the advisor committee’s vote against the treatment ...

Eisai and Biogen's Alzheimer's therapy Leqembi will be priced at $26,500 per year – a little less than misfired predecessor Aduhelm – after getting conditional authorisation for the drug from ...

The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Imagine being told there’s a drug that might save your life — but your insurance won’t cover it for 18 months. That’s the ...

Its portfolio includes treatments for multiple sclerosis, spinal muscular atrophy (Spinraza), Alzheimer’s disease (Aduhelm), ALS (QALSODY), and several biosimilars, with active collaborations ...

Leqembi, together with another Alzheimer's drug called Aduhelm, received approval from the US Food and Drug Administration in 2023.

A Boston College Center for Retirement Research report looks at the financial implications for Medicare of Alzheimer's drug Aduhelm The recent controversy over Alzheimer’s treatment Aduhelm—criticized ...

(It’s actually the second drug shown to do this; the first one was Aduhelm.) Amyloid plaque is a substance that may lead to tissue loss in parts of the brain related to memory, thinking ...